Melanoma in adolescents and young adults (AYAs) has distinct epidemiologic characteristics, with a declining incidence over the past 2 decades but an increasing trend in all-cause and cancer-specific mortality among specific populations, according to study results published in Clinics in Dermatology.
2025
Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma
Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.
Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma
EVENT REGION Illinois, Minnesota, Nebraska, Wisconsin
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.